Seven-year outcomes following aortic valve replacement with a novel tissue bioprosthesis

被引:9
|
作者
Beaver, Thomas [1 ]
Bavaria, Joseph E. [2 ]
Griffith, Bartley [3 ]
Svensson, Lars G. [4 ]
Pibarot, Philippe [5 ]
Borger, Michael A. [5 ]
Sharaf, Omar M. [1 ]
Heimansohn, David A. [6 ]
Thourani, Vinod H. [7 ]
Blackstone, Eugene H.
Puskas, John D. [8 ]
机构
[1] Univ Florida Hlth, Div Cardiovasc Surg, Gainesville, FL USA
[2] Hosp Univ Penn, Dept Cardiovasc Surg, Philadelphia, PA USA
[3] Univ Maryland, Med Ctr, Dept Surg, Baltimore, MD USA
[4] Cleveland Clin, Dept Thorac & Cardiovasc Surg, Cleveland, OH USA
[5] Laval Univ, Quebec Heart & Lung Inst, Dept Cardiol, Quebec City, PQ, Canada
[6] St Vincent Heart Ctr Indiana, Indianapolis, IN USA
[7] Piedmont Heart Inst, Marcus Valve Ctr, Dept Cardiovasc Surg, Atlanta, GA USA
[8] Mt Sinai Morningside, Dept Cardiovasc Surg, New York, NY USA
来源
关键词
aortic valve replacement; aortic valve disease; bioprosthetic valve; RESILIA tissue; PRESERVATION TECHNOLOGY; DEFINITIONS; GUIDELINES; DABIGATRAN; WARFARIN; FAILURE;
D O I
10.1016/j.jtcvs.2023.09.047
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: As bioprosthetic aortic valve replacement (AVR) extends to younger cohorts, tissue durability is of paramount importance. We report 7-year outcomes from an AVR bioprosthesis utilizing novel tissue. Methods: This was an international investigational device exemption trial for novel AVR with annual follow-up and a subset re-consented at 5 years for extended 10-year follow-up. Safety end points and echocardiographic measurements were adjudicated by an independent clinical events committee and by a dedicated core laboratory, respectively. Results: Between January 2013 and March 2016, 689 patients underwent AVR with the study valve. Mean age was 66.9 +/- 11.6 years, Society of Thoracic Surgeons risk score was 2.0% % +/- 1.8%, % , and 74.3% % of patients were New York Heart Association functional class II and III. Five-year follow-up was completed by 512 patients, and 225 re-consented for extended follow-up. Follow-up duration was 5.3 +/- 2.2 years (3665.6 patient-years), and 194 and 195 patients completed 6-and 7-year follow-ups, respectively. One-, 5-, and 7-year freedom from all-cause mortality was 97.7%, % , 89.4%, % , and 85.4%, % , respectively. Freedom from structural valve deterioration at 7 years was 99.3%. % . At 7 years, effective orifice fi ce area and mean gradients were 1.82 +/- 0.57 cm(2) (n = 153), and 9.4 +/- 4.5 mm Hg (n = 157), respectively. At 7 years, predominantly none (96.8% % [152 out of 157]) or trivial/trace (2.5% % [4 out of 157]) paravalvular regurgitation and none (84.7% % [133 out of 157]) or trivial/trace (11.5% % [18 out of 157]) transvalvular regurgitation were observed. Conclusions: We report the longest surgical AVR follow-up with novel tissue in an investigational device exemption trial utilizing an independent clinical events committee and an echocardiography core laboratory. This tissue demonstrates excellent outcomes through 7 years and is the benchmark for future surgical and transcatheter prostheses.
引用
收藏
页码:781 / 791
页数:11
相关论文
共 50 条
  • [21] Mid-term results of valve replacement with the ATS valve: A seven-year follow up
    Aoyagi, Shigeaki
    Hori, Hidetsugu
    Yoshikawa, Kazuhiro
    Arinaga, Koichi
    Fukunaga, Shuji
    JOURNAL OF HEART VALVE DISEASE, 2007, 16 (03): : 267 - 274
  • [22] Aortic valve replacement with the freestyle stentless bioprosthesis - Five-year experience
    Yun, KL
    Sintek, CF
    Fletcher, AD
    Pfeffer, TA
    Kochamba, GS
    Hyde, MR
    Torpoco, JO
    Khonsari, S
    CIRCULATION, 1999, 100 (19) : 17 - 23
  • [23] AORTIC-VALVE REPLACEMENT WITH BIOPROSTHESIS - 5-YEAR SURGICAL RESULT
    FROMER, M
    EGLOFF, L
    TURINA, M
    ROTHLIN, ME
    SCHWEIZERISCHE MEDIZINISCHE WOCHENSCHRIFT, 1988, 118 (09) : 313 - 318
  • [24] REPEAT REPLACEMENT OF AORTIC-VALVE BIOPROSTHESIS
    SAFI, HJ
    ILIOPOULOS, DC
    DUFF, DS
    ANNALS OF THORACIC SURGERY, 1995, 59 (05): : 1217 - 1218
  • [25] Percutaneous aortic valve replacement with the CoreValve bioprosthesis
    Zegdi, Rachid
    Achouh, Paul
    Fabiani, Jean-Noel
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 2008, 135 (06): : 1407 - 1408
  • [26] Thrombocytopenia Following Isolated Surgical Aortic Valve Replacement With Inspiris Resilia Bioprosthesis
    D'Alonzo, Michele
    Di Bacco, Lorenzo
    Baudo, Massimo
    D'Alonzo, Antonella
    Dossena, Yudit Tesfaye
    Rattenni, Francesco
    Muneretto, Claudio
    Rosati, Fabrizio
    TRANSLATIONAL MEDICINE AT UNISA, 2024, 26 (02):
  • [27] AORTIC-VALVE REPLACEMENT BY BIOPROSTHESIS WITH ENLARGEMENT OF THE AORTIC RING
    LESSANA, A
    AMEUR, A
    DUPRADEL, S
    RUFFENACH, A
    ADES, F
    LEFEVRE, JJ
    SVILARICH, V
    HERREMAN, F
    VIET, TT
    ARCHIVES DES MALADIES DU COEUR ET DES VAISSEAUX, 1984, 77 (03): : 324 - 329
  • [28] AORTIC-VALVE REPLACEMENT WITH STENTLESS PORCINE AORTIC BIOPROSTHESIS
    DAVID, TE
    POLLICK, C
    BOS, J
    JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 1990, 99 (01): : 113 - 118
  • [29] Seven-year outcomes following HIFU in patients with localized prostate cancer
    Uchida, Toyoaki
    Shoji, Sunao
    Nagata, Yoshihiro
    Terachi, Toshiro
    Illing, Rowland O.
    Emberton, Mark
    6TH INTERNATIONAL SYMPOSIUM ON THERAPEUTIC ULTRASOUND, 2007, 911 : 425 - +
  • [30] Midterm results after aortic valve replacement with a stentless bioprosthesis aortic valve
    Martinovic, I
    Everlien, M
    Farah, I
    Wittlinger, T
    Knez, I
    Greve, H
    Vogt, P
    ANNALS OF THORACIC SURGERY, 2005, 80 (01): : 198 - 203